NEW YORK, July 31 – Celera Diagnostics has sought marketing approval from the FDA for its HIV drug resistance system, the company announced Tuesday.

The premarket notification submission was made for Celera Diagnostics’ ViroSeq HIV-1 Genotyping System, an in vitro  method for detecting drug resistance in the HIV-1 virus genome.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.